Samsung Bioepis' Enbrel drug copy gets EU approval

SEOUL, Jan 17 (Reuters) - Samsung Bioepis Co Ltd said on Sunday it had received European Commission approval for its copy of the blockbuster biotech arthritis drug Enbrel.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.